Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Por:
Gargallo P, Bautista F, Juan-Ribelles A, Izquierdo E, Soriano A, de Rojas T, Escudero A, Lavarino C, Solano P, Hladun R, Rubio-San-Simón A, Martínez-Romera I, Calabria I, Gene-Olaciregui N, Castañeda-Heredia A, de Álava E, Pérez-Martínez A, Astigarraga I, Patiño-García A, Alonso J, Fernández-Teijeiro A, Cañete A and Moreno L
Publicada:
1 may 2022
Ahead of Print:
1 feb 2022
Resumen:
The study analyzes the current status of personalized medicine in pediatric oncology in Spain. It gathers national data on the tumor molecular studies and genomic sequencing carried out at diagnosis and at relapse, the centers that perform these studies, the technology used and the interpretation and clinical applicability of the results. Current challenges and future directions to achieve a coordinated national personalized medicine strategy in pediatric oncology are also discussed. Next generation sequencing-based (NGS) gene panels are the technology used in the majority of centers and financial limitations are the main reason for not incorporating these studies into routine care. Nowadays, the application of precision medicine in pediatric oncology is a reality in a great number of Spanish centers. However, its implementation is uneven and lacks standardization of protocols; therefore, national coordination to overcome the inequalities is required. Collaborative work within the Personalized Medicine Group of SEHOP is an adequate framework for encouraging a step forward in the effort to move precision medicine into the national healthcare system.
Filiaciones:
Gargallo P:
Research Institute Hospital La Fe, Valencia, Spain.
Oncology Department, Health in Code Group, Paterna, Valencia, Spain.
Bautista F:
Clinical Trials Unit, Pediatric Hematology-Oncology Division, Hospital Universitario Niño Jesús, Madrid, Spain
Juan-Ribelles A:
Pediatric Oncology and Hematology Unit, La Fe University Hospital, Valencia, Spain
Izquierdo E:
Pediatric OncoGenomics Unit, Pediatric Hematology-Oncology Department, Children's University Hospital Niño Jesús, Madrid, Spain
Soriano A:
Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
de Rojas T:
Pediatric OncoGenomics Unit, Pediatric Hematology-Oncology Department, Children's University Hospital Niño Jesús, Madrid, Spain
Escudero A:
Translational Research in Pediatric Oncology, Hematopoietic Stem Cell Transplantation, Cell Therapy, INGEMM-IdiPAZ, La Paz University Hospital, Madrid, Spain
Lavarino C:
Laboratory of Molecular Oncology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
Solano P:
Department of Pediatric Oncology, Hospital Infantil Virgen del Rocio, Sevilla, Spain
Hladun R:
Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Vall d'Hebron University Hospital, Barcelona, Spain
Rubio-San-Simón A:
Clinical Trials Unit, Pediatric Hematology-Oncology Division, Hospital Universitario Niño Jesús, Madrid, Spain
Martínez-Romera I:
Pediatric Hematology and Oncology Unit, Madrid Montepríncipe Hospital, Madrid, Spain
Calabria I:
Oncology Department, Health in Code Group, Paterna, Valencia, Spain
Gene-Olaciregui N:
Laboratory of Molecular Oncology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
Castañeda-Heredia A:
Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain
de Álava E:
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Sevilla/CIBERONC, Sevilla, Spain
Pérez-Martínez A:
Pediatric Hemato-Oncology Department, Hospital Universitario La Paz, Madrid, Spain
Astigarraga I:
Servicio de Pediatria, Bio Cruces Health Research Institute, Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain
Departamento de Pediatria, Universidad del Pais Vasco UPV/EHU, Leioa, Spain
Patiño-García A:
Laboratory and Department of Pediatrics, University Clinic of Navarra and Solid Tumor Area, CIMA, IdiSNA, Pamplona, Spain
Alonso J:
Instituto de Investigación de Enfermedades Raras and U758 (CB06/07/1009), CIBERER, Instituto de Salud Carlos III, Unidad de Tumores Sólidos Infantiles, Madrid, Spain
Fernández-Teijeiro A:
Pediatric Oncology and Hematology Unit, Hospital Universitario Virgen Macarena, Seville University, Seville, Spain
Cañete A:
Pediatric Oncology and Hematology Unit, La Fe University Hospital, Valencia, Spain
Moreno L:
Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Vall d'Hebron University Hospital, Barcelona, Spain
Green Submitted
|